Is there a role for HIPEC in ovarian cancer?
Author:
Publisher
Springer Science and Business Media LLC
Subject
Obstetrics and Gynaecology,General Medicine
Link
http://link.springer.com/article/10.1007/s00404-018-4908-0/fulltext.html
Reference12 articles.
1. Verwaal VJ, van Ruth S, de Bree E et al (2003) Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 21(20):3737–3743
2. Harter P, Mahner S, Hilpert F et al (2013) Statement by the Kommission OVAR of the AGO Study Group on the Use of HIPEC (Hyperthermic Intraperitoneal Chemotherapy) to Treat Primary and Recurrent Ovarian Cancer. Geburtshilfe Frauenheilkd 73(3):221–223
3. Harter P, du Bois A, Mahner S et al (2016) Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria and AGO Switzerland Regarding the Use of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer. Geburtshilfe Frauenheilkd 76(2):147–149
4. Quenet F, Elias D, Roca L. A Unicancer phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7. J Clin Oncol. 36;2018 (suppl; abstr LBA3503)
5. Spiliotis J, Halkia E, Lianos E et al (2015) Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann Surg Oncol 22(5):1570–1575
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Hyperthermic intraperitoneal chemotherapy for epithelial ovarian cancer: A meta-analysis;Gynecologic Oncology;2022-12
2. CRS and HIPEC in a patient with recurrent ovarian cancer after PDS and adjuvant chemotherapy, a case report and MDT discussion;European Journal of Gynaecological Oncology;2022
3. The Evolving Management of Peritoneal Surface Malignancies;Current Problems in Surgery;2021-04
4. Genetic association of gemcitabine/carboplatin-induced leukopenia and neutropenia in non-small cell lung cancer patients using whole-exome sequencing;Lung Cancer;2020-09
5. HIPEC in advanced epithelial ovarian cancer: why is there controversy?;Current Opinion in Oncology;2020-07-15
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3